Literature DB >> 33021724

Update on the Treatment of Ataxia: Medication and Emerging Therapies.

Susan L Perlman1.   

Abstract

While rehabilitation therapies always help patients with ataxia, there are currently no FDA-approved treatments for ataxia. Medications are available to treat symptoms that may complicate an ataxic illness, e.g., tremor, myoclonus, dystonia, and rigidity, which are discussed elsewhere in this volume. Spasticity, pain, fatigue, depression, sleep disturbances, cognitive decline, and bowel and bladder dysfunction, if they occur, all have multiple available drugs and therapies for symptomatic use. There is also an extensive literature on off-label uses of various medications to improve imbalance. The pipeline of emerging therapies for symptomatic and possible disease-modifying management of ataxia gives hope that we will soon see the first of many FDA-approved drugs for ataxic illnesses.

Entities:  

Keywords:  Ataxia; clinical trials; gene therapy; neurostimulation; rehabilitation

Year:  2020        PMID: 33021724      PMCID: PMC7851298          DOI: 10.1007/s13311-020-00941-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  53 in total

Review 1.  The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy.

Authors:  Jeremy D Schmahmann
Journal:  Neuropsychol Rev       Date:  2010-09-07       Impact factor: 7.444

Review 2.  Transcranial magnetic stimulation in hereditary ataxias: Diagnostic utility, pathophysiological insight and treatment.

Authors:  Roberto Rodríguez-Labrada; Luis Velázquez-Pérez; Ulf Ziemann
Journal:  Clin Neurophysiol       Date:  2018-06-15       Impact factor: 3.708

3.  Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial.

Authors:  Alberto Benussi; Valentina Dell'Era; Valentina Cantoni; Elisa Bonetta; Roberto Grasso; Rosa Manenti; Maria Cotelli; Alessandro Padovani; Barbara Borroni
Journal:  Neurology       Date:  2018-08-22       Impact factor: 9.910

Review 4.  Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities.

Authors:  Francisca Barake; Andrea Soza; Alfonso González
Journal:  Curr Opin Neurol       Date:  2020-06       Impact factor: 5.710

Review 5.  Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.

Authors:  Joel M Gottesfeld
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

6.  Grafted human chorionic stem cells restore motor function and preclude cerebellar neurodegeneration in rat model of cerebellar ataxia.

Authors:  Mohammadhosein Akhlaghpasand; Mahdi Tizro; Amir Raoofi; Arman Zeinaddini Meymand; Mohammaderfan Farhadieh; Fariba Khodagholi; Aysan Khatmi; Reza Soltani; Yadolah Hoseini; Ali Jahanian; Mahdi Eskandarian Boroujeni; Abbas Aliaghaei
Journal:  Metab Brain Dis       Date:  2020-02-15       Impact factor: 3.584

7.  Co-treatment with riluzole, a neuroprotective drug, ameliorates the 3-acetylpyridine-induced neurotoxicity in cerebellar Purkinje neurones of rats: behavioural and electrophysiological evidence.

Authors:  Mahyar Janahmadi; Iran Goudarzi; Mohammad Reza Kaffashian; Gila Behzadi; Yaqub Fathollahi; Sohrab Hajizadeh
Journal:  Neurotoxicology       Date:  2009-03-05       Impact factor: 4.294

Review 8.  Epigenetic cerebellar diseases.

Authors:  Mercedes Serrano
Journal:  Handb Clin Neurol       Date:  2018

Review 9.  The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force.

Authors:  Marie Beaudin; Antoni Matilla-Dueñas; Bing-Weng Soong; Jose Luiz Pedroso; Orlando G Barsottini; Hiroshi Mitoma; Shoji Tsuji; Jeremy D Schmahmann; Mario Manto; Guy A Rouleau; Christopher Klein; Nicolas Dupre
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

10.  Dysphagia Affecting Quality of Life in Cerebellar Ataxia-a Large Survey.

Authors:  M Rönnefarth; N Hanisch; A U Brandt; A Mähler; M Endres; F Paul; Sarah Doss
Journal:  Cerebellum       Date:  2020-06       Impact factor: 3.847

View more
  3 in total

1.  Therapeutic Advances in Movement Disorders.

Authors:  Caroline M Tanner; Jill L Ostrem
Journal:  Neurotherapeutics       Date:  2021-01-15       Impact factor: 7.620

Review 2.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

Review 3.  Hereditary Spastic Paraplegia: From Genes, Cells and Networks to Novel Pathways for Drug Discovery.

Authors:  Alan Mackay-Sim
Journal:  Brain Sci       Date:  2021-03-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.